Our meta-analysis comparing PD-1 plus chemotherapy and PD-L1 plus chemotherapy inhibitors in ES-SCLC patients demonstrates similar efficacy in terms of OS and PFS when combined with chemotherapy alone. The gene discussed is PDCD1; the disease is small cell lung carcinoma.